Physician profile
Mark A Dosmann
NPI 1245376219
$505.87
in general payments reported to CMS, 2019-2025
14 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.95 · 2023: $84.01 · 2024: $225 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $87.94 | 2019-2025 | Lynparza, Imfinzi |
| Daiichi Sankyo INC. | $54.05 | 2024-2025 | Datroway, Enhertu |
| Merck Sharp & Dohme LLC | $50.80 | 2023-2025 | Keytruda, Welireg |
| Regeneron Healthcare Solutions, INC. | $49.85 | 2024-2025 | Libtayo |
| Lilly USA, LLC | $46.71 | 2024 | Jaypirca, Verzenio, Retevmo |
| Sobi, INC | $39.68 | 2025 | |
| Incyte Corporation | $37.73 | 2024-2025 | Monjuvi, Zynyz |
| Astellas Pharma US INC | $31.08 | 2024 | Xospata |
| Seagen INC. | $21.16 | 2023 | Padcev |
| Karyopharm Therapeutics INC. | $18.69 | 2024 | Xpovio |
| Janssen Biotech, INC. | $18.36 | 2024 | Balversa, Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $18.27 | 2023 | |
| Genzyme Corporation | $16.10 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dosmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.